Blood thinner combo tested for leg artery disease
NCT ID NCT05009862
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 4 trial studied 60 people with peripheral artery disease (PAD) to see if adding low-dose rivaroxaban to aspirin improves blood vessel function and reduces clotting. Participants took either rivaroxaban plus aspirin or a placebo plus aspirin. The study measured changes in artery dilation and platelet activation using ultrasound and blood tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban (a blood thinner) plus aspirin
What this could lead to
If successful, this could show that low-dose rivaroxaban plus aspirin improves blood vessel health and reduces clotting risk in people with peripheral artery disease.
What could go wrong
This is a small, completed study (60 participants) looking at lab markers, not major clinical outcomes like heart attacks or amputations. Results may not translate to real-world benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States